Theory of operation

Our proprietary dynamic magnetic labelling (DML) method advances magnetic cell separation technology for rare cell enrichment applications and describes an active form of incubation of magnetic beads in a cell suspension.

Hereby, the incubation is carried out in the presence of specific series of changing magnetic fields and mixture of the suspension as to guide particle cell collision.

Key advantages 

  • Higher reaction kinetics reducing incubation times to 2 or 3 minutes (otherwise 5min to 2h).
  • No high gradient magnetic separation device  required
  • Higher and controllable reaction kinetics increasing binding efficiency of particles by several factors
  • Minimal non-specific binding, preventing loss of desired cells
  • First time system with controllable capture efficiency 

Ultra high enrichment is required when interfacing with current analytical methodology for investigations on circulating rare cells from blood of patients with solid tumors purposed to detect,quantify, characterize and/or cultivate for example circulating tumor cells. SanoLibio has imprinted the CD45 negative selection enrichment assay to our Walderbach Platform carrying out specialized automated cell separation. Hereby, almost all undesired nucleated cells (99.99% of leukocytes) from a blood sample are removed then exposing cells of the so called rare cell spectrum. The separation of undesired from desired cells and in consequence removal of noise is facilitated by magnetizing only undesired cells that become separable in the presence of a magnetic field. Once enriched, the desired cells are concentrated in 20uL to 30uL cell friendly solution and are ready for various downstream applications. 

CD45 negative selection with Walderbach

  • Minor loss of desired cells = isolation  of 1 rare cell in 100 million leukocytes
  • Fastest magnetic cell separation assay
  • Cheapest magnetic cell separation assay
  • Controllable capture efficiency from 80% to 99.99%

SanoLibio‚Äôs own liquid biopsy assay: Rarmax 

We use our Walderbach platform for our own liquid biopsy assay called Rarmax. In principle, the assay follows normal steps of removal of red blood cells and white blood cells then being able to analyse by immunofluorescence microscopy. The assay design followed hallmarks of high throughput, robustness, cost efficiency, simplicity, and highest sensitivity.